Can Aspirin Cause Bronchoconstriction?
Yes, aspirin can cause bronchoconstriction, particularly in susceptible individuals with Aspirin-Exacerbated Respiratory Disease (AERD), where it triggers sudden and often severe respiratory reactions through COX-1 inhibition. 1
Understanding the Mechanism
Aspirin causes bronchoconstriction through a well-defined pharmacologic mechanism, not through traditional IgE-mediated allergy. When aspirin inhibits the COX-1 enzyme, it removes the suppressive effect of prostaglandin E2, leading to:
- Overproduction of cysteinyl leukotrienes (the primary mediators of bronchoconstriction) 2
- Increased tryptase and histamine release
- Continued 5-lipoxygenase activity 1
The FDA drug label explicitly warns that aspirin may cause asthma (wheezing) as part of a severe allergic reaction 3, confirming this as a recognized adverse effect.
Who Is at Risk?
High-Risk Population: AERD Patients
Approximately 7% of adults with asthma and one-third of patients with both asthma and nasal polyposis have AERD 1. These patients characteristically present with:
- Chronic rhinosinusitis with nasal polyposis
- Asthma (often refractory)
- Acute respiratory reactions to aspirin/NSAIDs
- Anosmia
Upper and lower respiratory tract symptoms are frequently sudden and often severe after aspirin administration 1. The probability of reacting to formal aspirin challenge ranges from 80-100% in patients with a typical history 1.
Confirmation of Diagnosis
The diagnosis is primarily clinical. In patients with ≥2 respiratory reactions to different NSAIDs or a respiratory reaction requiring hospitalization, further diagnostic testing with aspirin challenge is unnecessary 1. The history alone is sufficient and definitive.
For uncertain cases, oral aspirin challenge can confirm the diagnosis, with reactions typically manifesting as:
- Drop in FEV₁ >10-15%
- Drop in peak nasal inspiratory flow >25%
- Wheezing, rhinorrhea, conjunctival injection 1
Clinical Implications
Cross-Reactivity Pattern
All COX-1 inhibiting NSAIDs cross-react to cause bronchoconstriction in AERD patients 1. This includes ibuprofen, naproxen, indomethacin, and other traditional NSAIDs. However, selective COX-2 inhibitors (like celecoxib) are extremely rare causes of reactions in AERD patients and can typically be taken safely 1.
Severity Considerations
Research demonstrates that aspirin-induced bronchoconstriction affects both large and small airways 4, with reactions typically peaking 60-90 minutes after oral administration 4. In one study, all patients with a history of aspirin causing severe reactions requiring hospitalization or ICU monitoring had positive oral aspirin challenges 1.
Safe Alternatives
The 2022 practice parameter guidelines suggest that selective COX-2 inhibitors may be used as alternative analgesics in patients with any NSAID hypersensitivity phenotype when an NSAID is needed 1. This recommendation carries low certainty of evidence but represents the safest approach for pain management in these patients.
Weakly selective COX-1 inhibitors like acetaminophen cause reactions in highly sensitive individuals only at higher doses (650-1000 mg) but are typically mild 1. Studies confirm that a positive history of aspirin intolerance is not associated with any detectable risk of acetaminophen intolerance 5.
Important Caveats
- AERD is rare in children and becomes increasingly common in adults with asthma 1
- The condition does not fit traditional allergic reaction categories—it is a pharmacologic reaction, not IgE-mediated 1
- Neither skin testing nor in vitro tests are useful for AERD diagnosis 1
- Despite aspirin avoidance, these patients typically experience refractory rhinosinusitis and asthma requiring aggressive medical management 1
The evidence is unequivocal: aspirin definitively causes bronchoconstriction in susceptible individuals through a COX-1 inhibition mechanism, with potentially severe consequences in AERD patients.